SDC1 and breast cancer: A further study showed that treatment with synstatin, a peptide inhibitor that disrupts the interaction of Sdc-1 with αvβ3 and αvβ5 integrins, impairs angiogenesis in vitro and in a mouse model of breast cancer [19].